Agenus Accelerates Phase 3 ROBBIN Trial for Neoadjuvant Colon Cancer with $85M Financing — Agenus Inc.

Event summary

Agenus completed an $85M private placement in July 2026 to support the Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer.
The ROBBIN trial targets approximately 38,000 newly diagnosed patients annually in the U.S. and over 200,000 worldwide, representing a $7B+ annual addressable sales opportunity.
Previously reported findings from NEST and UNICORN studies showed 30% pathologic complete response (pCR) and 40% major pathologic response (MPR) in BOT+BAL-treated patients.
Agenus discontinued funding for the BATTMAN Phase 3 study, shifting focus to ROBBIN trial execution.

The big picture

Agenus is betting heavily on the ROBBIN trial to validate its BOT+BAL combination in a large, underserved patient population with no new curative-intent therapies approved in over 20 years. The strategic shift away from the BATTMAN study underscores the company's focus on neoadjuvant settings, where it sees a significant market opportunity. The $85M financing provides a clear path to execute this strategy, but success hinges on delivering compelling data from the ROBBIN trial.

What we're watching

Trial Execution: The pace at which Agenus initiates and enrolls patients in the ROBBIN trial will determine its ability to meet regulatory milestones.
Financial Runway: Whether the $85M financing, potentially augmented by up to $255M from warrants, will be sufficient to support operations through 2031.
Competitive Positioning: How Agenus's focus on neoadjuvant therapy differentiates it in the crowded immuno-oncology space.